TY - JOUR
T1 - Divergent effect of the selective D3 receptor agonist pd-128,907 on locomotor activity in Roman high- and low-avoidance rats
T2 - Relationship to NGFI-A gene expression in the Calleja islands
AU - Guitart-Masip, Marc
AU - Johansson, Björn
AU - Fernández-Teruel, Albert
AU - Tobeña, Adolf
AU - Giménez-Llort, Lydia
N1 - Funding Information:
Acknowledgments We thank Professor Lars Terenius for wise advice on the manuscript preparation. This study was supported by grants from AFA (Stockholm, Sweden), Fundació Marató de TV3 014110, Programa Ramón y Cajal and Ericsson’s Foundation. Medical Psychology Unit is recipient of SGR-00071-2000. MG received a predoctoral FI scholarship from Generalitat de Catalunya. MG-M, AFT, AT and LG-L receive support from SAF2003-03480.
PY - 2008/1/1
Y1 - 2008/1/1
N2 - Rationale: The inbred Roman high- (RHA-I) and low-avoidance (RLA-I) rats, differing in dopaminergic activity and novelty/substance-seeking profiles, may be a suitable model to study the implication of the dopaminergic system in vulnerability to drug abuse. Differences in D3 receptor binding recently described between the two strains (Guitart-Masip M, Johansson B, Fernández-Teruel A, Cañete T, Tobeña A, Terenius L, Giménez-Llort L, Neuroscience 142:1231-1243, 2006b) may be important in shaping the aforementioned differences in novelty seeking. Objective: The aim of the present work was to study the effect of D3 receptor activation on novelty-induced locomotor activity in these two strains of rats. Materials and methods: We administered saline and PD-128,907 (0.01 and 0.1 mg/kg), a putative D3 receptor agonist, to the Roman rats and studied the locomotor activity when animals were placed in a novel environment. Thereafter, by means of in situ hybridization, nerve growth factor inducible clone A (NGFI-A) mRNA was measured in the striatum and the Calleja islands of these animals. Results: We found that RLA-I rats showed stronger locomotor inhibition than RHA-I rats after PD-128,907 administration. Moreover, RLA-I rats showed stronger reduction of NGFI-A mRNA in the Calleja islands than RHA-I rats. Conclusions: These results, together with previous findings, suggest that differences in D3 receptor expression in the Calleja islands may contribute to the divergent behavioral effect of PD-128,907 administration in the two strains of Roman rats. © 2007 Springer-Verlag.
AB - Rationale: The inbred Roman high- (RHA-I) and low-avoidance (RLA-I) rats, differing in dopaminergic activity and novelty/substance-seeking profiles, may be a suitable model to study the implication of the dopaminergic system in vulnerability to drug abuse. Differences in D3 receptor binding recently described between the two strains (Guitart-Masip M, Johansson B, Fernández-Teruel A, Cañete T, Tobeña A, Terenius L, Giménez-Llort L, Neuroscience 142:1231-1243, 2006b) may be important in shaping the aforementioned differences in novelty seeking. Objective: The aim of the present work was to study the effect of D3 receptor activation on novelty-induced locomotor activity in these two strains of rats. Materials and methods: We administered saline and PD-128,907 (0.01 and 0.1 mg/kg), a putative D3 receptor agonist, to the Roman rats and studied the locomotor activity when animals were placed in a novel environment. Thereafter, by means of in situ hybridization, nerve growth factor inducible clone A (NGFI-A) mRNA was measured in the striatum and the Calleja islands of these animals. Results: We found that RLA-I rats showed stronger locomotor inhibition than RHA-I rats after PD-128,907 administration. Moreover, RLA-I rats showed stronger reduction of NGFI-A mRNA in the Calleja islands than RHA-I rats. Conclusions: These results, together with previous findings, suggest that differences in D3 receptor expression in the Calleja islands may contribute to the divergent behavioral effect of PD-128,907 administration in the two strains of Roman rats. © 2007 Springer-Verlag.
KW - Calleja islands
KW - D receptors
KW - Locomotion
KW - NGFI-A
KW - PD-128,907
KW - Striatum
UR - http://www.scopus.com/inward/record.url?scp=38149112572&partnerID=8YFLogxK
U2 - 10.1007/s00213-007-0925-6
DO - 10.1007/s00213-007-0925-6
M3 - Article
C2 - 17952413
SN - 0033-3158
VL - 196
SP - 39
EP - 49
JO - Psychopharmacology
JF - Psychopharmacology
IS - 1
ER -
